Zacks Investment Research cut shares of Novozymes A/S – (NASDAQ:NVZMY) from a strong-buy rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “
Separately, Jefferies Group LLC set a $48.00 price objective on shares of Novozymes A/S – and gave the company a hold rating in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $50.00.
Shares of Novozymes A/S – (NASDAQ NVZMY) traded up 1.1253% on Wednesday, reaching $51.9885. The company had a trading volume of 746 shares. The firm has a market capitalization of $15.35 billion and a price-to-earnings ratio of 32.0126. The stock’s 50 day moving average is $48.79 and its 200 day moving average is $44.28. Novozymes A/S – has a 52 week low of $31.57 and a 52 week high of $52.04.
Novozymes A/S – (NASDAQ:NVZMY) last issued its earnings results on Friday, August 11th. The biotechnology company reported $0.36 EPS for the quarter, missing the Zacks’ consensus estimate of $0.39 by ($0.03). The firm had revenue of $522.72 million for the quarter. On average, equities analysts anticipate that Novozymes A/S – will post $1.71 EPS for the current year.
WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/09/21/novozymes-as-nvzmy-downgraded-by-zacks-investment-research-to-hold.html.
Novozymes A/S – Company Profile
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.
Receive News & Ratings for Novozymes A/S - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S - and related companies with MarketBeat.com's FREE daily email newsletter.